These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35925959)

  • 1. Experiences of sharing results of community based serosurvey with participants in a district of Maharashtra, India.
    Salvi N; Itta KC; Lachyan A; Hasan AZ; Prosperi C; Kumar MS; Wesley Vivian Thangaraj J; Kaduskar O; Bhatt V; Sapkal GN; Murhekar M; Gupta N; Mehendale S; Hayford K; Moss WJ; Chauhan S; Kulkarni R
    PLoS One; 2022; 17(8):e0271920. PubMed ID: 35925959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-campaign coverage evaluation of a measles and rubella supplementary immunization activity in five districts in India, 2019-2020.
    Thangaraj JWV; Prosperi C; Kumar MS; Hasan AZ; Kumar VS; Winter AK; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Soman B; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sarmah NP; Sharma S; Varghese A; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Chonker SK; Sangal L; Mehendale SM; Sapkal GN; Gupta N; Hayford K; Moss WJ; Murherkar MV
    PLoS One; 2024; 19(3):e0297385. PubMed ID: 38551928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia.
    Mutembo S; Carcelen A; Mwansa FD; Searle K; Wanyiri JW; Book C; Thuma PE; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2018 Dec; 99(6):1639-1642. PubMed ID: 30277204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
    Böttiger M; Christenson B; Strandell A; Romanus V
    Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 11. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do adolescents need a rubella vaccination campaign? Rubella serosurvey among healthy children in Hangzhou, China.
    Wang X; Xu Y; Zhang X; Zhang X; Du J; Che X; Gu W; Wang J; Jiang W; Liu Y
    Hum Vaccin Immunother; 2023 Aug; 19(2):2254536. PubMed ID: 37750387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
    Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
    Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Accuracy of Dried Blood Spots Collected on HemaSpot HF Devices Compared to Venous Blood Specimens To Estimate Measles and Rubella Seroprevalence.
    Prosperi C; Kaduskar O; Bhatt V; Hasan AZ; Vivian Thangaraj JW; Kumar MS; Sabarinathan R; Kumar S; Duraiswamy A; Deshpande GR; Padinjaremattathil Thankappan U; Chauhan SL; Kulkarni RN; Bansal AK; Chaaithanya IK; Salvi NR; Sharma S; Moss WJ; Sangal L; Gupta N; Murherkar MV; Mehendale SM; Sapkal GN; Hayford K
    mSphere; 2021 Aug; 6(4):e0133020. PubMed ID: 34259557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
    Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
    PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.